Adbry(Tralokinumab-ldrm)

Adbry is an interleukin-13 antagonist used for the treatment of moderate-to-severe atopic dermatitis (eczema) in adult individuals whose disease is not satisfactorily controlled with prescription therapies used on the skin (topical), or who are not recipients of topical therapies. Adbry injection can be considered with or without topical corticosteroids.

Recommended Dosage: Adbry is administered by subcutaneous injection. The recommended dosage is an initial dose of Adbry 600 mg (4 injections of Adbry 150 mg), followed by 300 mg (2 injections of Adbry 150 mg) given every other week. After 16 weeks of therapy, for patients with a body weight less than 100 kg who get clear or almost clear skin, a dosage of Adbry 300 mg injection every 4 weeks (28 days) may be considered. 

If a dose of Adbry is missed, administer the missed dose as quickly as possible. Thereafter, resume dosing with Adbry at the standard scheduled time.

• Hypersensitivity reactions (HSR) including angioedema and anaphylaxis may occur with the use of Adbry. In case of a serious hypersensitivity reaction, discontinue treatment immediately and start suitable therapy.
• Keratitis and conjunctivitis may occur more frequently in eczema subjects who received an Adbry injection 150 mg. Conjunctivitis (an eye disorder) may be reported most frequently. Patients should report new onset or any worsening symptoms related to the eye to their doctor.
• Patients must be treated with pre-existing helminth infections prior to starting treatment with Adbry. If patients are infected while on this treatment and do not react to antihelminth therapy, discontinue Adbry treatment until the infection resolves.
• This medicine may alter a patient’s immunity and enhance the risk of infection after the use of live vaccines. Before starting treatment with Tralokinumab-ldrm, do all age apt vaccinations as per current immunization guidelines. Do not use live vaccines in those treated with Adbry 150 mg. 

What documents are required to import ADBRY to India?

ADBRY (tralokinumab-ldrm) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic rep*orts
• Patients ID Proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
• Import permit if applicable

Is ADBRY available in India?

ADBRY (tralokinumab-ldrm injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Adbry injection in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

ADBRY can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Pune, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and other major cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of ADBRY (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Adbry injection price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements

Indian Pharma Network is able to source the ADBRY (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Adbry®?

Tralokinumab-ldrm is a Generic Name for the trade name drug Adbry®.

What is the Manufacturer’s Name of Adbry®?

Adbry® is manufactured by LEO Pharma Inc.

Is Adbry® approved by the FDA?

Yes, Adbry® is approved by the FDA. Date of first/initial approval: December 27, 2021.

Where can I get Adbry® at the best price in India?

To get the best Adbry 150 price in India, kindly get in touch with Indian Pharma Network (a WHO GDP & ISO 9001:2008 certified company). For Adbry 150 mg, a valid medical prescription is required from your treating physician.

What is the dosage and form of Adbry® supplied?

Adbry® is supplied as an Injection: 150 mg/mL solution in a single-dose prefilled syringe with a needle guard for subcutaneous administration. 

What are the most commonly reported side effects of Adbry®? 

The most commonly reported side effects of Adbry are conjunctivitis, upper respiratory tract infections, injection site reactions, and eosinophilia.

How much does Adbry cost in India?

The cost of Adbry 150 mg in India can vary. In order to procure this atopic dermatitis medicine legally, you can Call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Adbry®?

Store refrigerated at a temperature of 2 to 8°C (36 to 46°F) in the original carton in order to protect it from light.

Is it safe to buy Adbry® online in India?

Yes, one can buy Adbry 150 mg in India at the best price from the Indian Pharma Network (IPN) if Adbry 150 mg has not been launched or is unavailable in the country. We can help facilitate the Import of 150 mg Adbry through legal channels.